NDA 020816 · Sandoz
Azopt
Brinzolamide · Ophthalmic · Carbonic Anhydrase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Jun 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Apr 1, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
69
20 Phase 3, 1 recruiting
FAERS reports
8,693
5,215 serious, 645 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 24, 2023.
AZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. AZOPT is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. ( 1 )
Mechanism: Carbonic anhydrase is an enzyme found in many tissues of the body, including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II, found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 28, 2006 Supplement 9 · Efficacy · priority review Letter
- Apr 1, 1998 Original approval · Type 1 - New Molecular Entity Pediatric Medical ReviewPediatric Written RequestReview
1 products under this application
- AZOPT · BRINZOLAMIDE 1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Brinzolamide" as an intervention, any sponsor and status, largest first.
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01309204 · 1,184 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension; Vehicle and 2 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297920 · 1,062 participants · Start Mar 2011 · Primary completion Jun 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297517 · 1,001 participants · Start Feb 2011 · Primary completion Mar 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both EyesPivotal-lookingCompleted
Actavis Inc.Industry
NCT02512042 · 973 participants · Start Apr 2015 · Primary completion Apr 2016
Drug: Test-Brinzolamide 1% Ophthalmic suspension; Reference-Brinzolamide 1% Ophthalmic suspension · For: Glaucoma
Sites: Newport Beach, California; Largo, Florida; Miami, Florida · 10 sites in all
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01310777 · 771 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide 1% ophthalmic suspension and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT03896633 · 637 participants · Start Feb 28, 2018 · Primary completion Nov 17, 2018
Drug: brinzolamide 1% ophthalmic suspension; Azopt 1% · For: Glaucoma; Open Angle or Ocular Hypertension
Sites: Bridgewater, New Jersey
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Sun Pharmaceutical Industries LimitedIndustry
NCT05022004 · 599 participants · Start Dec 20, 2021 · Primary completion Dec 29, 2022
Drug: Brinzolamide ophthalmic suspension; Azopt® · For: Primary Open Angle Glaucoma; Ocular Hypertension
Sites: Srikakulam, India; Visakhapatnam, India; Ahmedabad, India · 40 sites in all
- A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00314158 · 523 participants · Start Nov 2005 · Primary completion Jan 2007
Drug: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension; Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension and 1 more · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Fort Worth, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure1,429
- dyspnoea590
- drug ineffective512
- dizziness503
- eye pain491
- fatigue476
- diarrhoea469
- fall454
- headache446
- vision blurred427
- asthenia416
- malaise396
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 26 |
| 2005 | 32 |
| 2006 | 58 |
| 2007 | 45 |
| 2008 | 84 |
| 2009 | 138 |
| 2010 | 183 |
| 2011 | 190 |
| 2012 | 242 |
| 2013 | 290 |
| 2014 | 368 |
| 2015 | 436 |
| 2016 | 550 |
| 2017 | 545 |
| 2018 | 673 |
| 2019 | 583 |
| 2020 | 1,947 |
| 2021 | 429 |
| 2022 | 490 |
| 2023 | 381 |
| 2024 | 421 |
| 2025 | 357 |
| 2026 | 225 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azopt (Brinzolamide)
2024 spending
$14.5M
Beneficiaries
8,968
30,493 claims
Per beneficiary
$1,615
$35.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $16,136,852 |
| 2023 | $21,806,627 |
| 2024 | $14,483,551 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis.
Liu Y, Zhao J, Zhong X, et al. · Front Pharmacol 2019 · Systematic Review
- Brimonidine-timolol versus brinzolamide-timolol for treatment of elevated intraocular pressure after phacoemulsification surgery.
Balsak S, Kaydu A, Erdem S, et al. · Int Ophthalmol 2018 · Randomized Controlled Trial
- Topical brinzolamide (Azopt) versus placebo in the treatment of infantile nystagmus syndrome (INS).
Hertle RW, Yang D, Adkinson T, et al. · Br J Ophthalmol 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Prophylactic effect of brinzolamide-brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections.
Dettoraki M, Rapti E, Fragkos D, et al. · Int Ophthalmol 2021 · Randomized Controlled Trial
- Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K, Ito K, Okawa C, et al. · J Glaucoma 2008 · Comparative Study, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.